Strata Skin Sciences (Strata Skin Sciences) Cash And Cash Equivalents : $6.78 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Strata Skin Sciences Cash And Cash Equivalents?

Strata Skin Sciences's quarterly cash and cash equivalents declined from Jun. 2023 ($9.03 Mil) to Sep. 2023 ($7.13 Mil) but then stayed the same from Sep. 2023 ($7.13 Mil) to Dec. 2023 ($6.78 Mil).

Strata Skin Sciences's annual cash and cash equivalents declined from Dec. 2021 ($12.59 Mil) to Dec. 2022 ($5.43 Mil) but then increased from Dec. 2022 ($5.43 Mil) to Dec. 2023 ($6.78 Mil).

Strata Skin Sciences Cash And Cash Equivalents Historical Data

The historical data trend for Strata Skin Sciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strata Skin Sciences Cash And Cash Equivalents Chart

Strata Skin Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

8.13

10.60

12.59

5.43

6.78

Strata Skin Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															5.43	2.83	9.03	7.13	6.78

Strata Skin Sciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Strata Skin Sciences (NAS:SSKN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Strata Skin Sciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Strata Skin Sciences (Strata Skin Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

E2OM:Germany E2OM:Germany

Address

5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website

https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

Executives

Shmuel Gov	officer: SVP & General Manager Carlsbad	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein	director	5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc.	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp	10 percent owner	590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz	officer: Chief Financial Officer	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia	director, officer: Chief Executive Officer	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker	director	5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang	director	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727